Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 156

1.
2.

Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia.

Fowler JA, Bettinger TL, Argo TR.

Clin Ther. 2008 Feb;30(2):231-48. doi: 10.1016/j.clinthera.2008.02.011. Review.

PMID:
18343262
3.

Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis.

Turkoz I, Bossie CA, Lindenmayer JP, Schooler N, Canuso CM.

BMC Psychiatry. 2011 Feb 7;11:21. doi: 10.1186/1471-244X-11-21.

4.

Paliperidone extended release: a review of its use in the management of schizophrenia.

Chwieduk CM, Keating GM.

Drugs. 2010 Jul 9;70(10):1295-317. doi: 10.2165/11204840-000000000-00000. Review.

PMID:
20568835
5.

Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial.

Kim SW, Chung YC, Lee YH, Lee JH, Kim SY, Bae KY, Kim JM, Shin IS, Yoon JS.

Int Clin Psychopharmacol. 2012 Sep;27(5):267-74. doi: 10.1097/YIC.0b013e328356acad.

PMID:
22809972
6.

Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release.

Pani L, Marchese G.

Expert Opin Drug Deliv. 2009 Mar;6(3):319-31. doi: 10.1517/17425240902780158. Review.

PMID:
19317589
7.

A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia.

Berwaerts J, Cleton A, Rossenu S, Talluri K, Remmerie B, Janssens L, Boom S, Kramer M, Eerdekens M.

J Psychopharmacol. 2010 Jul;24(7):1011-8. doi: 10.1177/0269881109106914. Epub 2009 Oct 13.

PMID:
19825908
8.

Switching from oral risperidone to flexibly dosed oral paliperidone extended-release: core symptoms, satisfaction, and quality of life in patients with stable but symptomatic schizophrenia: the RISPALI study.

Gattaz WF, Campos JA, Lacerda AL, Henna E, Ruschel SI, Bressan RA, de Oliveira IR, Rocha FL, Grabowski HM, Sacomani E Jr, Louzã MR, Quevedo J, Elkis H, Zorzetto Filho D, Périco Cde A, Lawson FL, Appolinário JC.

Curr Med Res Opin. 2014 Apr;30(4):695-709. doi: 10.1185/03007995.2013.869201. Epub 2013 Dec 16.

PMID:
24289141
9.
10.

Oral paliperidone extended-release: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability.

Citrome L.

Expert Opin Drug Metab Toxicol. 2012 Jul;8(7):873-88. doi: 10.1517/17425255.2012.693160. Epub 2012 May 25. Review.

PMID:
22632481
11.
12.

Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study.

Davidson M, Emsley R, Kramer M, Ford L, Pan G, Lim P, Eerdekens M.

Schizophr Res. 2007 Jul;93(1-3):117-30. Epub 2007 Apr 26. Erratum in: Schizophr Res. 2007 Nov;96(1-3):273-4.

PMID:
17466492
13.

Paliperidone extended release.

Yang LP, Plosker GL.

CNS Drugs. 2007;21(5):417-25; discussion 426-7. Review.

PMID:
17447829
14.

Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia.

Arakawa R, Ito H, Takano A, Takahashi H, Morimoto T, Sassa T, Ohta K, Kato M, Okubo Y, Suhara T.

Psychopharmacology (Berl). 2008 Apr;197(2):229-35. Epub 2007 Dec 6.

PMID:
18058087
15.

Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone.

Canuso CM, Youssef EA, Bossie CA, Turkoz I, Schreiner A, Simpson GM.

Int Clin Psychopharmacol. 2008 Jul;23(4):209-15. doi: 10.1097/YIC.0b013e3282fce651.

PMID:
18545059
16.

Paliperidone extended release: in adolescents with schizophrenia.

Perry CM.

Paediatr Drugs. 2012 Dec 1;14(6):417-27. doi: 10.2165/11209900-000000000-00000. Review.

PMID:
23050744
17.

Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension.

Tzimos A, Samokhvalov V, Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M.

Am J Geriatr Psychiatry. 2008 Jan;16(1):31-43. doi: 10.1097/JGP.0b013e31815a3e7a.

PMID:
18165460
18.

Paliperidone: An improvement over risperidone?

Dopheide JA.

Am J Health Syst Pharm. 2008 Mar 1;65(5):401. doi: 10.2146/ajhp070505. No abstract available.

PMID:
18281730
19.

Paliperidone extended-release: safety and tolerability from a metabolic profile perspective.

Rodríguez-Martínez A, Quilo CG.

Clin Drug Investig. 2013 Dec;33(12):867-76. doi: 10.1007/s40261-013-0100-2. Review.

PMID:
24241935
20.

Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens.

Fu DJ, Bossie CA, Kern Sliwa J, Ma YW, Alphs L.

Clin Schizophr Relat Psychoses. 2014 Jul;8(2):101-9, 109A. doi: 10.3371/CSRP.FUBO.022213.

PMID:
23446197
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk